| pubmed-article:15744718 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15744718 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:15744718 | lifeskim:mentions | umls-concept:C0021853 | lld:lifeskim |
| pubmed-article:15744718 | lifeskim:mentions | umls-concept:C0205054 | lld:lifeskim |
| pubmed-article:15744718 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15744718 | lifeskim:mentions | umls-concept:C0069456 | lld:lifeskim |
| pubmed-article:15744718 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15744718 | pubmed:dateCreated | 2005-4-19 | lld:pubmed |
| pubmed-article:15744718 | pubmed:abstractText | It was reported that the mean value of the extent of absolute oral bioavailability (F) of oltipraz at a dose of 20 mg/kg was 41.2% and only 2.68% of the oral dose was unabsorbed from the gastrointestinal tract in rats. Hence, the low F in rats could be due to considerable first-pass (gastric, intestinal and hepatic) effects. Hence, the first-pass effects of oltipraz were measured after intravenous, intraportal, intragastric and intraduodenal administration of the drug at a dose of 20 mg/kg to rats. The total area under the plasma concentration-time curve from time zero to time infinity (AUC) values between intragastric and intraduodenal administration (213 and 212 microg min/ml) in rats were almost similar, but the values were significantly smaller than that after intraportal administration (316 microg min/ml) in rats, indicating that gastric first-pass effect was almost negligible (due to negligible absorption of oltipraz from rat stomach), but the intestinal first-pass effect of oltipraz was considerable, approximately 32% of the oral dose. The hepatic first-pass effect of oltipraz was approximately 40% based on AUC values between intravenous and intraportal administration (319 versus 536 microg min/ml). Since approximately 65% of the oral oltipraz was absorbed into the portal vein, the value of 40% was equivalent to 25% of the oral dose. The low F of oltipraz in rats was mainly due to considerable hepatic and intestinal first-pass effects. | lld:pubmed |
| pubmed-article:15744718 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15744718 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15744718 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15744718 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15744718 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15744718 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15744718 | pubmed:month | May | lld:pubmed |
| pubmed-article:15744718 | pubmed:issn | 0142-2782 | lld:pubmed |
| pubmed-article:15744718 | pubmed:author | pubmed-author:KimSang GSG | lld:pubmed |
| pubmed-article:15744718 | pubmed:author | pubmed-author:KimJin WJW | lld:pubmed |
| pubmed-article:15744718 | pubmed:author | pubmed-author:KimYoon GYG | lld:pubmed |
| pubmed-article:15744718 | pubmed:author | pubmed-author:LeeMyung GMG | lld:pubmed |
| pubmed-article:15744718 | pubmed:author | pubmed-author:KimYoung HYH | lld:pubmed |
| pubmed-article:15744718 | pubmed:author | pubmed-author:BaeSoo KSK | lld:pubmed |
| pubmed-article:15744718 | pubmed:copyrightInfo | Copyright (c) 2005 John Wiley & Sons, Ltd. | lld:pubmed |
| pubmed-article:15744718 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15744718 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:15744718 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15744718 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15744718 | pubmed:pagination | 129-34 | lld:pubmed |
| pubmed-article:15744718 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:meshHeading | pubmed-meshheading:15744718... | lld:pubmed |
| pubmed-article:15744718 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15744718 | pubmed:articleTitle | Hepatic and intestinal first-pass effects of oltipraz in rats. | lld:pubmed |
| pubmed-article:15744718 | pubmed:affiliation | College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, San 56-1, Shinlim-Dong, Kwanak-Gu, Seoul 151-742, Republic of Korea. | lld:pubmed |
| pubmed-article:15744718 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15744718 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
